References
- Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral estrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990;65:282–5.
- Henriksson P, Carlström K, Pousette Å, Gunnarsson PO, Johansson CJ, Eriksson B, Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics and endocrine and clinical effects of a parenteral estrogen regimen. Prostate 1999;40:76–82.
- Henriksson P, Eriksson A, Stege R, Collste L, Pousette Å, von Schoultz B, Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 1988;13:257–61.
- Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) study no 5. Scand J Urol Nephrol 2008;442:220–9.
- Hedlund PO, Gustafson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt®) or conventional estrogen. Scand J Urol Nephrol Suppl 1980;55:103–5.
- Mikkola A, Aro J, Rannikko S, Ruutu M, on behalf of the Finnprostate Group. A high pretreatment plasma oestradiol level is associated with low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer. Br J Urol Int 2008;101:1090–5.
- Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scandinavian Prostatic Cancer Group study no 5. Scand J Urol Nephrol 2002;36:405–13.
- Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990;66:1017–21.
- Eisen M, Napp HE, Vock R. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate. J Urol 1975;114:93–7.
- Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448–56.
- Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelsson A. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 2010;28:3448–56.
- Blombäck M, Hedlund PO, Säwe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimes for prostate cancer – predictors for cardiovascular complications? Thromb Res 1988;49:111–21.
- Spetz AC, Hammar M, Lindberg B, Spångberg A, Varenhorst E. Scandinavian Prostate Cancer Group-5 trial study. Prospective evaluation of hot flashes during treatment with parenteral oestrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001;166:517–20.